Last reviewed · How we verify
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
The purpose of this study: Determining the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), pharmacokinetics characteristic, and dosage regimen of phase II/III of Chlorogenic acid for injection in the advanced malignant tumor subjects;
Details
| Lead sponsor | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 8 |
| Start date | 2014-09 |
| Completion | 2016-10 |
Conditions
- Advanced Cancer
Interventions
- Chlorogenic acid
Primary outcomes
- Number of adverse events — Within the first 60 days after the first dose of chlorogenic acid
Countries
China